Myopenia and Reduced Subcutaneous Adiposity in Children With Liver Disease Are Associated With Adverse Outcomes

Background Sarcopenia is defined as reduced skeletal muscle mass (SMM) or myopenia and altered muscle function and physical performance. It is unknown whether myopenia in children with end‐stage liver disease (ESLD) adversely impacts clinical outcomes. We hypothesized that myopenia was prevalent in...

Full description

Saved in:
Bibliographic Details
Published in:JPEN. Journal of parenteral and enteral nutrition 2021-07, Vol.45 (5), p.961-972
Main Authors: Ooi, Poh Hwa, Mazurak, Vera C., Bhargava, Ravi, Dunichand‐Hoedl, Abha, Ayala Romero, Rocio, Gilmour, Susan M., Yap, Jason YK, Mager, Diana R.
Format: Article
Language:English
Subjects:
body fat
gross motor delay
infection
low skeletal muscle mass
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Background Sarcopenia is defined as reduced skeletal muscle mass (SMM) or myopenia and altered muscle function and physical performance. It is unknown whether myopenia in children with end‐stage liver disease (ESLD) adversely impacts clinical outcomes. We hypothesized that myopenia was prevalent in children with ESLD and related to suboptimal nutrition intake contributing to gross motor and growth delay, increased hospitalization, and medical complications. Methods This retrospective study evaluated abdominal imaging (computed tomography/magnetic resonance imaging) for SMM (total, psoas, paraspinal, abdominal wall muscle; cm2/height2) and adipose tissue (total, visceral, subcutaneous adipose tissue [SAT], ) determinations at the third and fourth lumbar vertebrates during liver transplantation (LTx) assessment. ESLD children (n = 30) were age‐ and gender‐matched to healthy controls (n = 24). Myopenia was defined as SMM index z score
ISSN:0148-6071
1941-2444
DOI:10.1002/jpen.1963